DelveInsight’s “Opioid Induced Constipation (OSA) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Opioid Induced Constipation (OSA), historical and forecasted epidemiology as well as the Opioid Induced Constipation (OSA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Opioid Induced Constipation (OSA) market report provides current treatment practices, emerging drugs, Opioid Induced Constipation (OSA) market share of the individual therapies, current and forecasted Opioid Induced Constipation (OSA) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Opioid Induced Constipation (OSA) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Opioid Induced Constipation (OSA) market.
Some of the key facts of the opioid Induced Constipation Market:
According to Lang-Illievich et al. (2019), constipation is the most common side effect occurring during opioid use. Opioid-induced constipation (OIC) has a frequency of approximately 40%.
According to Laura Tasu ( 2017) , OIC in patients treated for noncancer pain has a prevalence of approximately 40% to 95%, and it is more likely to develop with a longer duration of opioid use.
Opioid-Induced Constipation Overview
The term Opioid-induced Constipation (OIC) is defined as a change from baseline in bowel habits after initiation of opioids that includes any of the following symptoms: reduced bowel movement frequency, development or worsening of straining to pass stool, a sense of incomplete rectal evacuation, and harder stool consistency.
Opioid-induced constipation (OIC) accounts from over 40% to 60% in patients without cancer receiving opioids. Studies showed that patients who developed OIC were more likely to be older, female, and unemployed. Opioid-induced constipation (OIC) occurs primarily via activation of enteric μ-receptors, which results in increased tonic non-propulsive contractions in the small and large intestine, increased colonic fluid absorption, and stool desiccation.
The three subclasses of opioid receptors include mu, delta, and kappa. All 3 receptors mediate their actions through coupling with G-protein receptors. In the GI tract, the mu and delta receptors predominate and are found in the myenteric and submucosal plexus. The opioid receptors stimulate the production of adenylate cyclase and inhibit the calcium channels, which in turn results in a decrease in neurotransmitter release. Tolerance to opioids not only develops to pain but also to the pharmacological effects on the GI tract.
Opioid-Induced Constipation Epidemiology Insights
Milce et al. (2016) found that OIC is the most frequent and bothersome symptom, it affects 60 to 90% of cancer patients with opioids, and between 10% and 20% of the population experiencing constipation at baseline.
According to Fabry and colleagues, approximately one-third of a representative French population had used opioids within the previous six months, and 9% of users had experienced OIC, which is more frequent in the case of regular use.
Opioid-Induced Constipation Epidemiology Segmentation
Opioid Induced Constipation diagnosed cases
Opioid Induced Constipation incident cases
Opioid Induced Constipation prevalent cases
Opioid Induced Constipation treatment cases
Opioid Induced Constipation gender-based cases
Opioid-Induced Constipation Market Outlook
The Opioid Induced Constipation (OSA) market outlook of the report helps to build a detailed comprehension of the historical, current and forecasted Opioid Induced Constipation (OSA) market trends by analyzing the impact of current Opioid Induced Constipation (OSA) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Opioid Induced Constipation (OSA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Opioid Induced Constipation (OSA) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Opioid Induced Constipation (OSA) market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Opioid Induced Constipation Market Trends
Opioid-Induced Constipation Key Companies
Develco Pharma Schweiz AG
And many others
Opioid Induced Constipation Therapies
Naloxone HCl PR
And many others
Table of Contents
Executive Summary of Opioid-Induced Constipation
Disease Background and Overview
Epidemiology and patient population
The United States
Opioid-Induced Constipation Emerging Therapies
Opioid-Induced Constipation Market Outlook
Market Access and Reimbursement of Therapies
Opioid-Induced Constipation Report Methodology
Click here to read more about Opioid Induced Constipation Market
Opioid Induced Constipation – Epidemiology Forecast to 2032
DelveInsight’s “Opioid Induced Constipation – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Opioid Induced Constipation epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States